• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Fat Tail Daily

Investment Ideas From the Edge of the Bell Curve

  • Menu
    • Commodities
      • Resources and Mining
      • Copper
      • Gold
      • Iron Ore
      • Lithium
      • Silver
      • Graphite
      • Rare Earths
    • Technology
      • AI
      • Bitcoin
      • Cryptocurrency
      • Energy
      • Financial Technology
      • Bio Technology
    • Market Analysis
      • Latest ASX News
      • Dividend Shares
      • ETFs
      • Stocks and Bonds
    • Macro
      • Australian Economy
      • Central Banks
      • World Markets
    • Small Caps
    • More
      • Investment Guides
      • Premium Research
      • Editors
      • About
      • Contact Us
  • Latest
  • Fat Tail Series
  • About Us
Technology Bio Tech

Incannex Healthcare Share Price Up on FDA Meeting (ASX:IHL)

Like 0

By Lachlann Tierney, Thursday, 25 March 2021

The pharmaceutical development company, Incannex Healthcare Ltd [ASX:IHL] share price is up after announcing a pre-IND meeting with the US FDA. At 2:30pm today, the IHL share price was up 5%...

Incannex Healthcare Ltd [ASX:IHL] shares are up after announcing a pre-IND meeting with the US FDA.

At 2:30pm today, the IHL share price was up 5%.

The pharmaceutical development company — specialising in medicinal cannabis pharmaceutical products and psychedelic therapies — continues its strong run this year, with Incannex shares up 35% YTD and up 570% over the last 12 months.

ASX IHL - Incannex Healthcare Share Price ChartSource: Tradingview.com

Incannex to meet with the FDA

Incannex announced today that it was granted a pre-IND (investigation new drug) meeting with the US Food and Drug Administration (FDA).

The meeting comes after the company submitted an information package about IHL-675A and the product’s proposed use in preventing acute respiratory distress syndrome (ARDS) caused by trauma and sepsis associated acute respiratory distress syndrome (SAARDS) caused by infection.

FDA informed Incannex it plans to comment on their development proposal by 21 April 2021.

FDA members from multiple divisions will offer feedback on the company’s entire development program.

Incannex explained that the purpose of the announced meeting is obtaining ‘regulatory guidance and agreement on the most efficient clinical development plan’ before submitting its IND application for IHL-675A.

Why is Incannex submitting the IND application?

Incannex stated in the release that patients diagnosed with ARDS currently suffer poor treatment outcomes.

Oxygen ventilators are used to treat symptoms but according to Incannex, not the ‘underlying inflammation “feedback loop” that causes the fluid leakage.’

IHL believes that its IHL-675A directly targets the lung inflammation.

IHL share price outlook

Today’s announcement didn’t state that IHL is entering FDA’s second stage, only that the FDA is willing to meet Incannex and guide it in preparation for the company’s IND application.

According to the FDA, the IND application is the second stage in a 12-stage drug approval process.

Should the pre-IND meeting go well and should IHL pass the second stage, it will have to conduct human-trial studies that will first involve 20–80 people, then a few dozen to 300 people, and finally several hundred to about 3,000 people, according to the FDA.

This will likely take some time and will surely involve some bumps along the road.

Investors with long-time horizons will likely find it easier to hold IHL shares all through Incannex’s FDA approval journey.

That said, securing FDA approval will be a big boost to the company as it seeks to carve out market share in an emerging market.

IHL is surely aware of the journey ahead but believes it can ‘harness increasing regulatory enthusiasm for promising medicinal cannabinoid and psychedelic therapies.’

ASX pot stocks are catching the eyes of investors seeking growth markets. If you are interested in pot stocks and wish to research the growing CBD healthcare industry and what investing opportunities are out there, then this free report is highly recommended.

Well worth a read!

Regards,

Lachlann Tierney,
For Money Morning

 

All advice is general advice and has not taken into account your personal circumstances.

Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

Comments

Subscribe
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments
Lachlann Tierney

Lachlann’s Premium Subscriptions

Publication logo
Fat Tail Investment Research

Latest Articles

  • The Untold Tariff Story
    By Callum Newman

    The real tariff story isn't what you're reading in the headlines. It's not about short-term market volatility or quarterly earnings impacts. The true story – and the massive investment opportunity – is about the fundamental restructuring of American manufacturing that's now underway. Trump's tariffs are accelerating AI adoption in American industry. Today, I want to show you the companies that are emerging as the backbone of this transformation.

  • The Big Payday: Chasing Profits in Risky Places
    By James Cooper

    Geologist, James Cooper, draws on a key metric he uses to understand the real-time position in the commodity cycle. Read on to find out more.

  • China’s plan to pop the AI bubble and sink Mag7 for good
    By Nick Hubble

    Back in January, China’s Artificial Intelligence program DeepSeek triggered a trillion-dollar meltdown in US AI stocks in a single day. What if this was just the beginning?

Primary Sidebar

Latest Articles

  • The Untold Tariff Story
  • The Big Payday: Chasing Profits in Risky Places
  • China’s plan to pop the AI bubble and sink Mag7 for good
  • The latest Closing Bell is available now
  • Iron Ore Stocks: Opportunity if You Have a Strategy

Footer

Fat Tail Daily Logo
YouTube
Facebook
x (formally twitter)
LinkedIn

About

Investment ideas from the edge of the bell curve.

Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.

Quick Links

Subscribe

About

FAQ

Terms and Conditions

Financial Services Guide

Privacy Policy

Get in Touch

Contact Us

Email: support@fattail.com.au

Phone: 1300 667 481

All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.

Fat Tail Logo

Fat Tail Daily is brought to you by the team at Fat Tail Investment Research

Copyright © 2025 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988